Axonics Inc at Piper Sandler Healthcare Conference Transcript
All right. We're going to get started here. Good afternoon, everyone. My name is Adam Maeder. I'm one of the medtech analysts here at Piper Sandler. Very pleased to introduce the next panelists. We have Dan Dearen, President and Chief Financial Officer; and Ray Cohen, CEO from Axonics. Gentlemen, thanks so much for joining us.
Thank you. Thanks for the invite. We appreciate it, and good morning.
Questions & Answers
And good morning. Yeah. Maybe I'm losing track of time here. I guess, it's still technically morning. Guys, so maybe just a good place to start is Q3 results -- so a nice beat and raised quarter. The guidance implies for Q4, I think, $74 million and [change]. I think that's a step-up of about 5% sequentially, quarter over quarter. You had a double-digit step-up sequentially in Q4 last year versus Q3.
So maybe just walk through some of the puts
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |